Treatment of acute pancreatitis with beta-adrenergic agonist drugs.
An increase in microvascular permeability may be important in the pathogenesis of acute pancreatitis. beta-adrenergic receptor agonist drugs are known to inhibit the increase in microvascular permeability induced by histamine and related vasoactive substances. These inflammatory mediators have been shown to be released during the course of experimental and human pancreatitis. We investigated the effect of isoproterenol and terbutaline sulfate on the development of acute edematous (AEP) and acute hemorrhagic (AHP) pancreatitis in a feline model of biliary pancreatitis. When given at the time of pancreatic insult, isoproterenol prevented the development of both AEP and AHP. Both isoproterenol and terbutaline sulfate reduced the severity of pancreatic inflammation, even when given up to 12 hours after the onset of AEP. Although neither drug was effective in treating established AHP, our findings suggest that, if given early in the course of the disease, they may be useful in preventing the progression of AEP to AHP.
D000208:Acute Disease; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000818:Animals; D002415:Cats; D015232:Dinoprostone; D004487:Edema / Q000517:prevention & control; D006470:Hemorrhage / Q000517:prevention & control; D006632:Histamine; D007545:Isoproterenol / Q000627:therapeutic use; D010195:Pancreatitis / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D011458:Prostaglandins E; D013726:Terbutaline / Q000627:therapeutic use; D013997:Time Factors
D000318:Adrenergic beta-Agonists; D011458:Prostaglandins E; D006632:Histamine; D015232:Dinoprostone; D007545:Isoproterenol; D013726:Terbutaline